Saturday, May 17, 2025 – Global burden and strength of evidence for 88 risk factors in204 countries and 811 subnational locations, 1990–2021 : a systematic analysis for the Global Burden of Disease Study 2021 Lancet May 18, 2024 GBD 2021…
Saturday, May 17, 2025 – ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT: OVERCOMING CHALLENGES IN ORAL DELIVERYFebruary 14, 2025By Adare Pharmaceuticals Obesity is a significant global health challenge that requires lifestyle changes and effective pharmacological treatments to overcome. Human glucagon-like peptide 1…
Friday, May 16, 2025 – This talk at the discuss the development of new medications designed to address muscle loss that can occur alongside weight loss achieved with GLP-1 receptor agonists like semaglutide and tirzepatide. While these powerful weight loss drugs are effective, a significant portion…
Friday, May 16, 2025 – According to an article in Medscape Medical News, a study presented at the AACE 2025 conference indicates that individuals treated for obesity using semaglutide (Wegovy) may experience a significantly lower risk of fractures compared to those who undergo sleeve gastrectomy.…
Friday, May 16, 2025 – Are you wanting to save some money? Discouraged by the high price of the GLP-1 drugs from the big pharmaceutical companies and the compounding pharmacies? Here is an overview of what to expect in creating…
Thursday, May 15, 2025 – Experts warn that current methods of making the peptide drugs are environmentally unfriendly April 28, 2024 by Aayushi Pratap Chemical & Engineering News, Volume 102, Issue 13 This article explores the significant environmental challenges associated…
Wednesday, May 14, 2025 – Anazco D, Acosta A. Precision medicine for obesity: current evidence and insights for personalization of obesity pharmacotherapy. Int J Obes (Lond). 2025 Mar;49(3):452-463. doi: 10.1038 Epub 2024 Aug 10. PMID: 39127792; PMCID: PMC11931505. Published 10…
Monday, May 12, 2025 – This academic paper examines whether tailoring anti-obesity medication based on specific patient characteristics, or “phenotypes,” improves weight loss outcomes compared to standard treatment. Researchers classified individuals with obesity into four main phenotypes: “hungry brain” (abnormal satiation), “emotional hunger” (hedonic…
Monday, May 12, 2025 – This paper describes a phase 3b clinical trial comparing tirzepatide and semaglutide for weight management in adults with obesity but without diabetes. The SURMOUNT-5 trial randomly assigned participants to receive either tirzepatide or semaglutide weekly for 72 weeks. Tirzepatide was found to be superior to semaglutide in…
Sunday, May 11, 2025 – The common belief is that as GLP-1s become more popular, that will stimulate competition in generics and new drug development. This is all good, right? However, this has not always been true. This news article…